INVESTORS

Investor Relations

Recent News

May 15, 2019

Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO

- SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1st - - Sierra to hold Analyst & Investor Event at 6:00 am CT on June 3rd...

May 8, 2019

Sierra Oncology Reports First Quarter 2019 Results

Momelotinib regulatory pathway clarity anticipated in Q2 2019 - - SRA737 Phase 1/2 preliminary clinical data anticipated at the 2019 ASCO Annual Meeting - VANCOUVER, May 8, 2019 /CNW/ - Sierra...

May 6, 2019

Sierra Oncology to Attend Two Investor Conferences in May

Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...

View all news releases

Latest Presentation

Targeted Therapeutics for Hematology & Oncology – Q2 2019

View All Presentations

Events and Webcasts

SRA737 Analyst & Investor Event

Monday, June 3, 2019

6:00am - 7:00am CDT

Location: History event room, Marriot Marquis Hotel, 2121 S Prairie Ave, Chicago, Illinois RSVP to attend in-person:...

Add to Calendar

Set Email Reminder

View all events and webcasts